AAAAAA

   
Results: 1-8 |
Results: 8
PEMPHIGUS-VULGARIS IN A HUMAN-IMMUNODEFICIENCY-VIRUS-INFECTRED PATIENT
Authors: CAPIZZI R MARASCA G DELUCA A TACCONELLI E CAUDA R ROTOLI M
Citation: R. Capizzi et al., PEMPHIGUS-VULGARIS IN A HUMAN-IMMUNODEFICIENCY-VIRUS-INFECTRED PATIENT, Dermatology, 197(1), 1998, pp. 97-98
PHASE-II STUDY OF TRIMETREXATE, FLUOROURACIL, AND LEUCOVORIN FOR ADVANCED COLORECTAL-CANCER
Authors: BLANKE CD KASIMIS B SCHEIN P CAPIZZI R KURMAN M
Citation: Cd. Blanke et al., PHASE-II STUDY OF TRIMETREXATE, FLUOROURACIL, AND LEUCOVORIN FOR ADVANCED COLORECTAL-CANCER, Journal of clinical oncology, 15(3), 1997, pp. 915-920
RANDOMIZED TRIAL OF CARBOPLATIN PLUS AMIFOSTINE VERSUS CARBOPLATIN ALONE IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: BUDD GT GANAPATHI R ADELSTEIN DJ PELLEY R OLENCKI T PETRUS J MCLAIN D ZHANG JL CAPIZZI R BUKOWSKI RM
Citation: Gt. Budd et al., RANDOMIZED TRIAL OF CARBOPLATIN PLUS AMIFOSTINE VERSUS CARBOPLATIN ALONE IN PATIENTS WITH ADVANCED SOLID TUMORS, Cancer, 80(6), 1997, pp. 1134-1140
STIMULATION OF HEMATOPOIESIS BY AMIFOSTINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
Authors: LIST AF BRASFIELD F HEATON R GLINSMANNGIBSON B CROOK L TAETLE R CAPIZZI R
Citation: Af. List et al., STIMULATION OF HEMATOPOIESIS BY AMIFOSTINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME, Blood, 90(9), 1997, pp. 3364-3369
USE OF AMIFOSTINE IN BONE-MARROW PURGING
Authors: CAGNONI PJ JONES RB BEARMAN SI ROSS M HAMI L FRANKLIN WA CAPIZZI R SCHEIN PS SHPALL EJ
Citation: Pj. Cagnoni et al., USE OF AMIFOSTINE IN BONE-MARROW PURGING, Seminars in oncology, 23(4), 1996, pp. 44-48
AMIFOSTINE - PROTECTION FROM HEMATOTOXICITY AND NEPHROTOXICITY INDUCED BY CHEMOTHERAPY
Authors: OSTER W SCHEFFLER B CAPIZZI R SCHEIN P
Citation: W. Oster et al., AMIFOSTINE - PROTECTION FROM HEMATOTOXICITY AND NEPHROTOXICITY INDUCED BY CHEMOTHERAPY, European journal of cancer, 31A, 1995, pp. 83-83
AMIFOSTINE - A NEWLY DEVELOPED ENTITY FOR CHEMOPROTECTION (PROTECTIONFROM HEMATO, NEPHROTOXICITY, OTOTOXICITY AND NEUROTOXICITY)
Authors: OSTER W HABBOUBI N SCHEFFLER B CAPIZZI R SCHEIN P
Citation: W. Oster et al., AMIFOSTINE - A NEWLY DEVELOPED ENTITY FOR CHEMOPROTECTION (PROTECTIONFROM HEMATO, NEPHROTOXICITY, OTOTOXICITY AND NEUROTOXICITY), Experimental hematology, 23(8), 1995, pp. 843-843
AMIFOSTINE (WR-2721) SHORTENS THE ENGRAFTMENT PERIOD OF 4-HYDROPEROXYCYCLOPHOSPHAMIDE-PURGED BONE-MARROW IN BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW SUPPORT
Authors: SHPALL EJ STEMMER SM HAMI L FRANKLIN WA SHAW L BONNER HS BEARMAN SI PETERS WP BAST RC MCCULLOCH W CAPIZZI R MITCHELL E SCHEIN PS JONES RB
Citation: Ej. Shpall et al., AMIFOSTINE (WR-2721) SHORTENS THE ENGRAFTMENT PERIOD OF 4-HYDROPEROXYCYCLOPHOSPHAMIDE-PURGED BONE-MARROW IN BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW SUPPORT, Blood, 83(11), 1994, pp. 3132-3137
Risultati: 1-8 |